A new targeted drug delivery system called TAR-200 has shown remarkable results in a phase 2 clinical trial, eliminating tumors in 82% of patients with high-risk non-muscle-invasive bladder cancer that had resisted prior treatment.
In most cases,…
Continue Reading
News Source: www.sciencedaily.com
Leave a Reply